1-15 of 266
Recognizing Telomere Biology Disorders in Familial Pulmonary Fibrosis
Clinician's RoundtableRecognizing Telomere Biology Disorders in Familial Pulmonary Fibrosis
Pilar Rivera-Ortega, MD
Myeloid Mutations in ALL: Disease Risk and Prognostic Implications
Project Oncology®Myeloid Mutations in ALL: Disease Risk and Prognostic Implications
Caner Saygin, MD
How Myeloid Mutations in ALL Inform Treatment Decisions
Project Oncology®How Myeloid Mutations in ALL Inform Treatment Decisions
Caner Saygin, MD
The Long Road to an FCS Diagnosis
On the Frontlines of Familial Chylomicronemia SyndromeThe Long Road to an FCS Diagnosis
Charles Turck, PharmD, BCPS, BCCCP
Peter P. Toth, MD, PhD, FAAFP, FICA, FAHA, FNLA, FCCP, FACC
Could It Be FCS? Recognizing the Diagnostic Clues
On the Frontlines of Familial Chylomicronemia SyndromeCould It Be FCS? Recognizing the Diagnostic Clues
Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Zahid Ahmad, MD, FNLA
Familial Chylomicronemia Syndrome: Improving Recognition and Diagnosis
On the Frontlines of Familial Chylomicronemia SyndromeFamilial Chylomicronemia Syndrome: Improving Recognition and Diagnosis
Steve Jackson, PharmD
Nivedita Patni, MD
- advertisement
Optimizing Screening Pathways for Alpha-1 Antitrypsin Deficiency
Clinician's RoundtableOptimizing Screening Pathways for Alpha-1 Antitrypsin Deficiency
Alexandria May, PharmD, BCPS
Michael Czarnecki, MD
How to Increase Testing Rates for Alpha-1 Antitrypsin Deficiency
Clinician's RoundtableHow to Increase Testing Rates for Alpha-1 Antitrypsin Deficiency
Brian P. McDonough, MD, FAAFP
Brooks Kuhn, MD, MAS
A Phenotype-Driven Approach to Alpha-1 Antitrypsin Deficiency Care
Clinician's RoundtableA Phenotype-Driven Approach to Alpha-1 Antitrypsin Deficiency Care
Brian P. McDonough, MD, FAAFP
MeiLan Han, MD, MS
Predicting PPD Risk: A Biomarker-Based Approach
Advances in Women's HealthPredicting PPD Risk: A Biomarker-Based Approach
Jennifer L. Payne, MD
Conference Coverage at ICCBH 2026: A New Frontier in Achondroplasia—Clinical Insights From the PROPEL 3 Trial of Oral Infigratinib in Children
EndocrinologyConference Coverage at ICCBH 2026: A New Frontier in Achondroplasia—Clinical Insights From the PROPEL 3 Trial of Oral Infigratinib in Children
Ravi Savarirayan, MBBS, MD
How Genetic Testing Guides Personalized mBC Care
On the Frontlines of Metastatic Breast CancerHow Genetic Testing Guides Personalized mBC Care
Alexandria May, PharmD, BCPS
Marie Wood, MD
- advertisement
Evaluating Port-Wine Capillary Malformations in Children
On the Frontlines of Pediatric Skin HealthEvaluating Port-Wine Capillary Malformations in Children
Kristen Kelly, MD
Alexandria May, PharmD, BCPS
Recognizing ATTR-CM in High-Risk Populations
On the Frontlines of ATTR-CMRecognizing ATTR-CM in High-Risk Populations
Steve Jackson, PharmD
Frederick Ruberg, MD
Multidisciplinary Coordination in TK2d Diagnosis and Management
NeuroFrontiersMultidisciplinary Coordination in TK2d Diagnosis and Management
Charles Turck, PharmD, BCPS, BCCCP
Zarazuela Zolkipli-Cunningham, MBChB, MRCP
Oscar H. (Hank) Mayer, MD
